ホーム>>Signaling Pathways>> GPCR/G protein>> TSH Receptor>>Org41841

Org41841

カタログ番号GC32423

Org41841 は、黄体形成ホルモン/絨毛性ゴナドトロピン受容体 (LHCGR) と甲状腺刺激ホルモン受容体 (TSHR) の両方の部分アゴニストであり、EC50 はそれぞれ 0.2 および 7.7 μM です。

Products are for research use only. Not for human use. We do not sell to patients.

Org41841 化学構造

Cas No.: 301847-37-0

サイズ 価格 在庫数 個数
1mg
$214.00
在庫あり
5mg
$342.00
在庫あり
10mg
$540.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively.

Functional assays demonstrate that Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively. Treatment of L570F with Org41841 reveals an improved EC50 of 800 nM. M9 responds to Org41841 with an improved EC50 of 2700 nM and a greatly improved efficacy for signaling to 99% of the maximal value observed for thyroid-stimulating hormone (TSH) stimulation of thyroid-stimulating hormone receptor (TSHR)[1].

[1]. Holger Jaschke, et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor(LHCGR). J Biol Chem. 2006 Apr 14;281(15):9841-4.

レビュー

Review for Org41841

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Org41841

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.